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Abstract 
Purpose: The purpose of the study was to implement and prospectively evaluate the 
outcomes of a rapid genomic diagnosis program at two pediatric tertiary centers. 
Methods: Rapid singleton whole-exome sequencing (rWES) was performed in 
acutely unwell pediatric patients with suspected monogenic disorders. Laboratory 
and clinical barriers to implementation were addressed through continuous 
multidisciplinary review of process parameters. Diagnostic and clinical utility and 
cost-effectiveness of rWES were assessed. 
Results: Of 40 enrolled patients, 21 (52.5%) received a diagnosis, with median time 
to report of 16 days (range 9–109 days). A result was provided during the first 
hospital admission in 28 of 36 inpatients (78%). Clinical management changed in 12 
of the 21 diagnosed patients (57%), including the provision of lifesaving treatment, 
avoidance of invasive biopsies, and palliative care guidance. The cost per diagnosis 
was AU$13,388 (US$10,453). 
Additional cost savings from avoidance of planned tests and procedures and 
reduced length of stay are estimated to be around AU$543,178 (US$424,101). The 
clear relative advantage of rWES, joint clinical and laboratory leadership, and the 
creation of a multidisciplinary “rapid team” were key to successful implementation. 
Conclusion: Rapid genomic testing in acute pediatrics is not only feasible but also 
cost-effective, and has high diagnostic and clinical utility. It requires a whole-of-
system approach for successful implementation. 
Key Words: clinical utility; cost-effectiveness; implementation; rapid; whole-exome 
sequencing 
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INTRODUCTION 
Genetic conditions are the leading cause of death in infants and children in the 
developed world. Rare genetic disease diagnosis has been transformed by next-
generation sequencing (NGS) technologies, including whole-exome sequencing 
(WES) and whole-genome sequencing (WGS), which are increasingly available as 
clinical tests. Despite common perceptions that rare genetic conditions are 
untreatable, early genomic diagnosis provides prognostic information, influences 
management decisions, and alters clinical outcomes1. Studies limited to infants, 
primarily recruited from neonatal and pediatric intensive-care units (NICUs and 
PICUs)1-6, have consistently reported high diagnostic yields (30–73%), and NICUs 
have been highlighted as priority implementation areas for genomic medicine7,8. 
Turnaround times for results appear to impact on clinical utility: results were clinically 
useful in 32.6% of diagnosed patients when WES was provided, with standard 
turnaround times (median 136 days)1, and clinically useful in 65–71% of diagnosed 
patients in rapid WGS (rWGS) and rapid WES (rWES) studies, where results were 
provided with median turnaround times of 12 –23 days3,5,6.  
The consistent delivery of timely and accurate results in the acute pediatric setting 
presents challenges for both clinical and laboratory services. The barriers to 
implementing genomic medicine in clinical practice are well documented9, but there 
are few studies describing practical implementation experience10-12. Reports of 
implementation experience in rapid genomics have focused primarily on the 
technical aspects of delivering results in less than 2 days as a proof of principle7,13. 
Furthermore, while several studies have used modeling in retrospectively and 
prospectively ascertained cohorts to argue that genomic sequencing can reduce 
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investigation costs in rare-disease diagnosis14-18 an actual impact of standard or 
rapid genomic sequencing on health care costs has not been demonstrated. 
We developed and implemented an rWES diagnosis program at two tertiary pediatric 
hospitals using an accredited clinical test, with the aim of delivering rWES results in 
less than 21 days from study enrollment. We sought to prospectively evaluate patient 
-focused outcomes, assessing diagnostic and clinical utility and cost-effectiveness, 
as well as to conduct a formative process evaluation to identify and implement 
clinical and laboratory practices required to achieve rapid diagnostics. 
 
MATERIALS AND METHODS 
Study design and participants 
Participants were recruited during clinical care by the clinical genetics services at the 
two tertiary pediatric hospitals in Melbourne, Australia: the Royal Children’s Hospital 
(RCH) and Monash Children’s Hospital (MCH), between April 2016 and September 
2017. RCH has 250 inpatient beds, a 45-bed NICU, and a 28-bed PICU, whereas 
MCH has 230 inpatient beds and a 64-bed NICU. The patient-selection criteria are 
summarized in Table 1. 
Table 1 about here 
Potential participants were discussed by a panel of study investigators (Z.S., T.Y.T., 
A.Y., and S.M.W.) to determine eligibility, with a minimum of two clinical geneticists 
agreeing rWES was appropriate required for a patient to be enrolled. A core data set, 
including Human Phenotype Ontology (HPO) terms, was collected at enrollment and 
recorded using PhenoTips19. All diagnostic investigations, including those planned, 
were collected from referring clinicians and from the medical records. 
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A phenotype-driven list of candidate genes for prioritized analysis was nominated for 
each participant by their clinician, as previously described.20 Information regarding 
the impact of rWES diagnosis on patient management was collected from the 
clinicians involved in each participant’s care.  
Exome sequencing, data analysis and interpretation  
Singleton rWES was performed at our National Association of Testing Authorities-
accredited laboratory (VCGS Pathology), using SureSelect CRE exome capture 
(Agilent, Santa Clara, CA) on either HiSeq 4000 or NextSeq 500 sequencers 
(Illumina, San Diego, CA). The mean coverage obtained was 100 ×. Variants were 
characterized using the Melbourne Genomics Health Alliance shared bioinformatics 
pipeline, Cpipe21 version 2.0.1. Variant filtering and prioritization were performed as 
previously described.1,20 Only variants relevant to a participant’s phenotype were 
assessed with regard to pathogenicity. The data for each patient were reviewed by 
the referring clinical geneticist and a study clinical geneticist (Z.S.) in addition to the 
curating medical genomic scientist in order to prioritize variants for assessment. 
Criteria for classification were based on the principles outlined in the American 
College of Medical Genetics and Genomics standards for interpretation of sequence 
variants22. Variant classifications were reviewed in a multidisciplinary team (MDT) 
meeting attended by clinical geneticists, other medical subspecialists, genetic 
counselors, medical genomic scientists and bioinformaticians. The quorum for an 
MDT meeting was the curating medical genomic scientist, one senior medical 
genomic scientist, and one clinical geneticist. 
Cost-effectiveness 
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Cost data were collected as previously described15,18. A clinical geneticist at each 
recruitment site (Z.S. and A.Y.) extracted all investigations, procedures, and 
assessments carried out for diagnostic purposes from the medical records. 
Costs of investigations and patient encounters were obtained from the hospital, state 
government, Medical Benefits Schedule, and from testing laboratories. (The costs of 
individual investigations are presented in Supplementary Table S1 online). Average 
diagnostic costs per patient and cost per diagnosis were calculated. Bootstrapping 
using 500 replications was performed to estimate confidence intervals. The baseline 
cost of a day in an intensive-care unit (ICU) for a ventilated patient (AU$4,500) was 
used in calculations regarding savings arising from reduced length of stay following 
rapid diagnosis. 
Costs were compared with those ascertained in our previously published study of an 
infant cohort undergoing the usual investigations and WES with standard turnaround 
times (sWES) in parallel15  Specifically, we compared against the cost per diagnosis 
of usual care (including single-gene and multigene panel testing) as already 
published, and in addition calculated the cost per diagnosis of usual diagnostic care 
with sWES replacing all sequencing tests in that cohort. 
Process evaluation 
We conducted a formative evaluation to identify clinical and laboratory barriers to 
implementation. Information was collected on the following clinical service 
parameters as measured from the day of patient admission to tertiary pediatric 
hospital: time to clinical genetics referral, time to clinical genetics assessment, time 
to proposing patient for rWES, time to approval by patient approval panel, time to 
consent. These were collectively considered to be “time to ascertainment.” 
Information was also collected on laboratory service parameters as measured from 
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the day on which sample and consent were made available to the laboratory: time to 
initiate sequencing, time to complete bioinformatics analysis, time to MDT review, 
and time to issue report. These were collectively considered to be “time to report.” 
Time to ascertainment and time to report were together taken as the “time to 
diagnosis.” Times are reported as calendar days. 
The clinical and laboratory leads of the project (Z.S. and S.L.) reviewed the clinical 
and laboratory-service performance parameters following each case to identify 
delays and opportunities for improvement. Quarterly MDT meetings between the 
clinical geneticists, genetic counselors, specimen reception staff, and laboratory 
genomic scientists involved in the project were used to present patient outcomes, 
review service performance parameters, and discuss solutions to implementation 
barriers. Barriers and solutions were mapped to the relevant constructs of the 
Consolidated Framework for Implementation Research (CFIR). The CFIR is a 
conceptual framework that draws together multiple existing implementation 
models and enables systematic assessment of implementation barriers and 
facilitators across 39 constructs arranged in five domains (inner setting, outer setting, 
intervention characteristics, individuals’ characteristics, and process)23. The CFIR 
has been adopted by the Implementing Genomics in Practice Network to promote 
the comprehensive and shareable evaluation of implementation experiences in 
clinical genomics24. 
Statistical analysis 
Descriptive statistics were used to describe the demographic features, time course, 
and outcomes of the rWES and sWES cohorts. Dot plots were used to visualize the 
distribution of variables to determine whether to use parametric or nonparametric 
measures. Mean and standard deviation were determined for normally distributed 
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variables. For non-normally distributed variables median and interquartile ranges 
were calculated. Power calculations were performed to compute power for the given 
sample size and values of the control-group and experimental-group proportions. 
Differences were investigated using two-sided t-tests for normally distributed 
variables, Wilcoxon-rank sum test for non-normally distributed variables, or chi-
squared tests for categorical variables. P values are reported for results where 
Po0.05. All analyses were performed using Stata 11.0 (Stata, College Station, TX). 
Ethics approval 
The study was part of the Melbourne Genomics Health Alliance project 
(http://www.melbournegenomics.org.au ) and received Human Research Ethics 
Committee approval (13/MH/326). Parents provided written informed consent after 
genetic counseling regarding the testing. 
 
RESULTS 
Participant demographics and indications for testing 
A total of 46 patients were considered for rWES, 40 of whom were enrolled in the 
study. One patient was excluded owing to a prior completed sequencing-based test, 
and another was enrolled in an alternative genomic project. One patient was judged 
to have a low likelihood of a monogenic condition, and another did not meet 
complexity criteria. All but one of the families who were offered rWES accepted 
testing, although during pretest counseling several families expressed unwillingness 
to accept that their child could have a genetic condition (G.R.B., A.J., Y.P., J.E., 
personal observations). The one family who declined testing recontacted our team 
within a week to request rWES. Two approved patients died before sequencing 
started. Their samples were excluded from the rWES study and were processed 
using standard turnaround times. 
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The characteristics of enrolled participants and indications for testing are 
summarized in Table 2, and are compared with data from our previously published 
sWES infant cohort.1 Thirty-three patients (83% of the cohort) were recruited from 
RCH and the remainder from MCH. The median age at enrollment was 28 days 
(range 3 days to 4 years). 
Table 2 about here 
 
Diagnostic performance of rWES 
rWES resulted in a molecular diagnosis of 23 conditions in 21 patients, with a 
diagnostic rate of 52.5% (Supplementary Table S2). All pathogenic and likely 
pathogenic variants identified in this study have been deposited in ClinVar with 
supporting evidence for pathogenicity (https://www.ncbi.nlm. nih.gov/clinvar/; 
submission ID: SUB3209813). Novel missense variants concordant with phenotype 
were identified in an additional three patients but currently do not meet American 
College of Medical Genetics and Genomics pathogenicity criteria (Supplementary 
Table S3).  
rWES outperformed biochemical tests in two patients. It returned a diagnostic result 
of AADC deficiency (MIM 608643) in one patient in 14 days, enabling treatment to 
bestarted, while the cerebrospinal fluid neurotransmitter result sent to an interstate 
laboratory became available after 10 weeks. In another patient, a diagnosis of 
ECHS1 deficiency (MIM 616277) was made in 15 days, while the typical diagnostic 
pattern on urine metabolic screening was obscured in the acute setting by ketosis 
and acidosis and became apparent only once the patient was stable and the rWES 
diagnosis prompted retesting. 
Impact on clinical management 
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rWES led to change in management in 12 diagnosed participants (Supplementary 
Table S2 online). This included the provision of lifesaving treatment in one patient 
diagnosed with riboflavin transporter defect, who at the time of diagnosis was 
ventilation-dependent via a tracheostomy. rWES was initiated on day 46 of 
admission to PICU, with a result available after 21 days. The patient was treated with 
riboflavin and discharged from the hospital after 179 days.  
Nine patients (23%) died in the course of the study: three from the undiagnosed 
group and six from the diagnosed group. Five died before results were available and 
four after results were available. The result from rWES was instrumental in 
management being redirected toward palliation in the acute-care setting in two 
patients. One baby was relinquished for adoption, with the rWES diagnosis of a 
syndromic condition contributing to the parental decision. 
In six patients, uninformative rWES, sometimes combined with improvement in 
clinical course, contributed to the diagnosis of a non-monogenic condition. Two of 
these patients avoided invasive tissue biopsies (lung and liver), which were 
scheduled but postponed owing to the availability of rWES (Supplementary Table S3 
online). 
Cost-effectiveness 
The cost of providing rWES was AU$3,959 per patient. The total cost of diagnostic 
assessments and investigations, including rWES, in this cohort, was AU$281,143 
and the cost per diagnosed patient was AU$13,388 (Table 3).  
Table 3 about here 
Three patients avoided invasive tissue biopsies as a result of rWES being available. 
The combined cost of these biopsies is estimated to be AU$2,428.43. In another 
patient, orders for Prader-Willi methylation studies (AU$250) and nerve conduction 
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studies (AU$500) were cancelled following an rWES diagnosis. The patient treated 
for riboflavin transporter defect is estimated to have avoided an additional 115 days 
in PICU because the rWES result was provided in 21 days as opposed to the 136 
days it would have taken for an sWES result. Based on a cost of AU$4,500 per day 
for a ventilated patient in a PICU, the total cost savings for this patient can be 
estimated to be around AU$517, 500. For one of the patients, whose care was 
redirected toward palliation, the rWES result became available at the same time as a 
diagnostic anatomical pathology result, and therefore the rWES result is not 
considered to have altered the length of stay in an ICU. However, in the second 
patient, the diagnosis of a neurodegenerative condition prompted earlier redirection 
of care to palliation. Consensus medical opinion from the treating team is that the 
length of stay in the ICU was reduced by at least 5 days (AU$22,500). The total cost 
savings in this cohort are therefore estimated to be around AU$543,178. 
Barriers to rWES implementation and solutions implemented 
A number of clinical and laboratory barriers to rWES implementation were identified 
throughout the study. These, and the solutions implemented, are presented in Table 
4 and temporally illustrated in relation to the test turnaround times in Figure 1.  
Table 4 and Figure 1 about here 
Key strategies included utilizing the relative advantage of rWES to engage team 
members in changing work practices; appointing formal implementation leaders to 
clearly define the project goals and identify problems and solutions using processes 
of continuous reflection and evaluation, resulting in the creation of a dedicated 
network (“rapid team”) with its own dedicated communication strategy and standard 
operating procedures. These strategies delivered efficiency gains without an 
increase in test cost. Costs were increased through the allocation of additional 
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resources to obtain further reductions in time to report—in particular, the dynamic 
use of HiSeq and NextSeq instruments to enable more flexible batching of samples, 
with 21 of 40 samples (52%) sequenced on NextSeq. Several parts of the program 
benefited from increased flexibility on the part of clinical and laboratory staff to deal 
with single urgent cases at short notice, as well as willingness to change working 
patterns, for example, by increasing the deployment of genetic counselors in the 
inpatient setting. Successful implementation was also dependent on staff being able 
to adapt established working patterns, for example, by defining quorum requirements 
for patient approval and multidisciplinary variant review meetings to enable rapid 
single-case processing while maintaining quality. Demonstrating the relative 
advantage of rWES in terms of clinical utility and cost-effectiveness to referrers and 
clinical geneticists was an important factor in achieving reductions in time to 
ascertainment. 
Impact on clinician time 
Referrals for inpatient genetics consultation at our principal recruitment center (RCH) 
have nearly doubled during the course of the study, from 150 per year in 2014 to 273 
in 2016; a further increase is observed in 2017, with 150 inpatients referred in the 
first 6 months alone. The average number of genetic counselor–inpatient contacts 
per rWES family was 1.8 (range 0–4 contacts), and overall duration 68 min (range 
15–150 min). The average number of clinical geneticist–inpatient contacts per rWES 
family was 4 (range 1–6 contacts), with an estimated 30 min spent with families who 
did not receive a diagnosis and 90 min with those who received a diagnosis. 
 
DISCUSSION 
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We have demonstrated that rapid genomic-sequencing results have the power to 
deliver actual reductions in cost per diagnosis by altering the diagnostic pathway. At 
AU$13,388 per diagnosis, a diagnosis by rWES costs half that of diagnosis by usual 
care in our previously reported infant cohort (AU$27,050.36).15 It is also comparable 
to the cost per diagnosis of sWES (AU$10,843.60) in that cohort, despite the higher 
cost of rWES and the selection of high-complexity patients. The increased cost of 
rWES was offset by reductions in the number of outpatient subspecialist 
assessments, imaging and anatomical pathology tests for diagnostic purposes. 
The majority of results were delivered during the child’s initial tertiary hospital 
presentation, affording the opportunity to influence early management in 57% of 
diagnosed patients, delivering more personalized care. Given the high cost of ICU 
admission, rapid genomic sequencing results have the power to produce large 
savings by altering lengths of stay, and the overall cost savings from rWES, 
AU$543,178, far exceeded the cost of providing rWES in the entire cohort 
(AU$157,960). It is likely that further reductions in both time to ascertainment and 
time to result will deliver additional cost savings.  
Other groups have highlighted the value of rapid genomic results in redirecting care 
toward palliation5. However, we found that the majority of such decisions in our 
cohort were made on clinical grounds, often before a result was available. Australia 
has some of the highest reported rates of withdrawal and withholding of medical 
treatment in the pediatric setting25. Australian ICU clinicians may be accustomed to 
counseling families about palliation in the absence of a secure diagnosis and hence 
generally did not defer palliation discussions until rWES results were available. 
Many of the barriers to implementation of genomic medicine have been well 
described; they include insufficient sequencing, bioinformatics, data interpretation, 
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and workforce capacity and capability, as well as lack of evidence for effectiveness 
and lack of funding9 . Rapid genomic sequencing not only magnifies existing 
bottlenecks and barriers but poses additional laboratory and clinical challenges 
through the introduction of time pressure in systems that are still evolving and lack 
absorptive capacity26. Using an implementation framework, CFIR, allowed the 
systematic and comprehensive identification of clinical and laboratory barriers 
throughout the study. This practical approach provided an opportunity to identify and 
implement a broad range of real-time solutions and strategies to optimize 
effectiveness of implementation in a timely manner. Overcoming obstacles to deliver 
an rWES service in a clinical setting required change in the work patterns of all 
health professionals involved, including ICU clinicians, clinical geneticists, clinical 
genetics trainees, genetic counselors, specimen reception staff, bioinformaticians, 
and laboratory genomic scientists. This was facilitated by the formation of a joint 
clinical and laboratory implementation leadership. The clear relative advantage of 
rWES in terms of clinical utility and cost-effectiveness proved to be a powerful 
engagement tool with other subspecialist groups. Finally, successful implementation 
in our setting required the creation of a defined multidisciplinary network (rapid 
team), which developed standard operating procedures, established dedicated 
communication channels, and engaged in continuous reflection and evaluation, 
creating a virtuous cycle through precision medicine, implementation science, and a 
learning health-care system27. 
From a laboratory perspective, our experience demonstrates that 10-fold 
improvements in WES turnaround times can be achieved through efficiency gains, 
and supplementary use of smaller-capacity sequencers. The use of such sequencers 
to alleviate batching issues has been highlighted by other groups attempting rapid 
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genomics5 and largely accounted for doubling the per-sample cost to AU$3,959 in 
our setting. The median time to result of 16 days is comparable to that achieved by 
other groups utilizing singleton5 or trio WGS,6 or trio WES3 of 12–23 days. 
Decreasing time to result beyond the best (9 days) achieved here would require 
instituting 24-hour, 7-days-per-week sample processing and analysis, and true 
“on-demand” sequencing independent of batching considerations, as well as 
deploying specialized infrastructure, such as dedicated rapid analysis bioinformatics 
pipelines13. While our study utilized singleton WES to contain costs, we consider trio 
sequencing to be necessary for rapid turnaround results, to allow the immediate and 
final classification of a number of recessive and de novo variants and potentially 
increase diagnostic yield28. Similarly, although we used sequential single-nucleotide 
polymorphism microarray and rWES to contain costs, there are patients in whom the 
pretest probability of chromosomal abnormality is low and testing can proceed in 
parallel. Ultimately, WGS may be the preferred testing modality for rapid genomics 
owing to its ability to provide both copy-number and single-nucleotide variation data, 
despite the difference in cost, which is currently considerable. 
From a clinical perspective, timely diagnosis relies not only on the ability to process 
rWES samples in the laboratory but also on timely and appropriate patient selection 
and test initiation. Clinical genetics is typically perceived as a nonacute outpatient 
medical specialty. Although most clinical genetics services provide inpatient and out-
of-hours consultation, there has traditionally been little expectation for urgent clinical 
genetics opinion or test results. We have prioritized access to genomic testing for 
patients early in the diagnostic trajectory as a first-tier sequencing test since 2014,1,18 
and specifically prioritized inpatients in ICUs. We have observed a doubling in the 
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number of referrals to our inpatient service, particularly since the introduction of 
rWES, and an increase in the number of patient/family contacts by clinical geneticists 
and genetic counselors occurring in the inpatient setting. As test turnaround times 
continue to decrease, we can anticipate greater demand for out-of-hours genetic 
services. Resourcing the increase in demand for inpatient clinical genetics 
consultations and upskilling ICU clinicians in appropriate test initiation and consent 
would both be important ingredients for the success of rapid genomic-sequencing 
programs. 
From a genetic counseling perspective, the acute setting reduces or eliminates 
counselors’ opportunity for preparatory information-gathering regarding family 
medical and psychosocial history. Families are frequently highly distressed by their 
child being acutely unwell, while being simultaneously faced with complex decisions 
regarding diagnostic investigations, immediate treatment, long-term management, 
and/or palliation. Concerns have also been raised about the potential for genomic 
testing in the newborn period to alter family dynamics29 . Traditionally, we have 
deferred complex genetic testing in this patient group to the ambulatory setting 
following discharge or death, which may have provided parents valuable processing 
time. Despite these concerns, we found a very high rate of acceptance of genomic 
testing by families. Factors influencing uptake of genomic testing are likely to be 
complex and would benefit from further study, particularly across different health-
care settings and implementation models. 
This study is limited by its small size. As the numbers of patients requiring rapid 
testing are low even in major tertiary pediatric centers, full evaluation of effectiveness 
and of implementation approaches would be facilitated by multicentre studies. In 
terms of health economic evaluation, the greatest difficulty is in accurately capturing 
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the impact of rWES on clinical trajectory and length of stay; cohorts tend to be 
heterogeneous and include many patients with ultrarare conditions, with poorly 
understood natural history. Evaluation of rapid genomic testing would be enhanced 
by collection of additional parameters such as family experience, empowerment, and 
decisional regret.  
Rapid genomic testing challenges traditional clinical and laboratory genetics service 
models and requires a whole-of-system approach for successful implementation. Our 
study extends the body of evidence indicating that the provision of rapid genomic 
results in acute pediatric care is feasible and has high diagnostic and clinical utility. 
Importantly, we demonstrate cost savings from a clinical rapid WES program. 
Barriers to implementation are likely to be common across health-care systems and 
we identify solutions for these that were successful in our setting. Developing the 
capability to reliably produce rapid genomic results for selected patients has 
applications outside of acute pediatric care, notably in the oncology and prenatal 
settings, and requires substantial investment to further optimize test performance 
and equity of access  
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FIGURE LEGENDS 
Figure 1. Clinical and laboratory barriers to delivering rapid genomic diagnosis 
service identified during the study. 
Figure 2. Solutions implemented to deliver whole-of-system change required for 
rapid genomic diagnosis service. 
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